11,361 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd acquired a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 11,361 shares of the biopharmaceutical company’s stock, valued at approximately $3,759,000.

Other large investors also recently added to or reduced their stakes in the company. iA Global Asset Management Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 979.5% during the 4th quarter. iA Global Asset Management Inc. now owns 17,780 shares of the biopharmaceutical company’s stock worth $7,070,000 after purchasing an additional 16,133 shares during the last quarter. Perpetual Ltd acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter valued at about $2,004,000. WINTON GROUP Ltd grew its holdings in shares of Alnylam Pharmaceuticals by 92.5% in the third quarter. WINTON GROUP Ltd now owns 6,800 shares of the biopharmaceutical company’s stock valued at $3,101,000 after purchasing an additional 3,267 shares during the period. Linden Advisors LP acquired a new stake in Alnylam Pharmaceuticals during the third quarter worth about $6,550,000. Finally, Jain Global LLC increased its position in Alnylam Pharmaceuticals by 366.5% during the third quarter. Jain Global LLC now owns 78,046 shares of the biopharmaceutical company’s stock worth $35,589,000 after purchasing an additional 61,316 shares during the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the transaction, the director directly owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. The trade was a 70.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.86% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. Wells Fargo & Company boosted their target price on shares of Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the company an “equal weight” rating in a report on Friday, May 1st. Weiss Ratings raised shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Royal Bank Of Canada decreased their price objective on Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating on the stock in a report on Friday, May 1st. Jefferies Financial Group reiterated a “hold” rating and issued a $330.00 price objective (down from $522.00) on shares of Alnylam Pharmaceuticals in a research report on Monday, March 16th. Finally, Chardan Capital reissued a “buy” rating and set a $425.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 25th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $461.39.

Alnylam Pharmaceuticals Stock Up 1.7%

ALNY traded up $5.44 during trading hours on Tuesday, hitting $318.48. 255,764 shares of the company’s stock were exchanged, compared to its average volume of 1,247,000. Alnylam Pharmaceuticals, Inc. has a 12-month low of $273.11 and a 12-month high of $495.55. The firm has a 50 day moving average of $295.49 and a 200 day moving average of $327.31. The firm has a market cap of $42.52 billion, a P/E ratio of 87.04 and a beta of 0.27. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, beating the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The company had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same quarter last year, the company posted ($0.44) EPS. The firm’s revenue was up 96.4% compared to the same quarter last year. Analysts predict that Alnylam Pharmaceuticals, Inc. will post 7.36 EPS for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.